Clinical Trials on B-Cell Non-Hodgkin Lymphoma in United Kingdom

Total 7934 results

Memorial Sloan Kettering Cancer Center

Completed

Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL

Lymphoma | B-cell Non-Hodgkin's Lymphoma

United States
Masonic Cancer Center, University of Minnesota

Completed

ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL

Diffuse Large B Cell Non-Hodgkin Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

Diffuse Large B-Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Mantle Cell Lymphoma | B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Transformed Non-Hodgkin Lymphoma

United States
Pfizer

Completed

Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell

United States, Spain, France, Switzerland, United Kingdom, Belgium, Germany
Hoffmann-La Roche

Completed

An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma, Follicular Lymphoma

United Kingdom, Belgium, United States, Australia, Canada, Germany
National Cancer Institute (NCI)

Terminated

T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma

Lymphoma, B-Cell | Chronic Lymphocytic Leukemia | Lymphoma, Non-hodgkins | B-Cell Chronic Lymphocytic Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies

Diffuse Large B-Cell Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Indolent Non-Hodgkin Lymphoma | CD20-Positive Neoplastic Cells Present | Refractory Mature B-Cell Non-Hodgkin Lymphoma

United States
Medical University of South Carolina

Recruiting

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

Chronic Lymphocytic Leukemia | B-cell Non Hodgkin Lymphoma

United States
BioInvent International AB

Recruiting

A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma

Indolent B-Cell Non-Hodgkin Lymphoma

Spain, United States, Brazil, Sweden, Germany, Poland
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma

CD20-positive B-cell Non-Hodgkin Lymphoma

United States, France
David Bond, MD
Bristol-Myers Squibb

Active, not recruiting

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Diffuse Large B-Cell Lymphoma | Aggressive Non-Hodgkin Lymphoma | Indolent Non-Hodgkin Lymphoma | Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma | High Grade B-Cell Lymphoma, Not Otherwise Specified | Transformed Non-Hodgkin Lymphoma | Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma | Ann Arbor Stage... and other conditions

United States
Medical College of Wisconsin
Miltenyi Biomedicine GmbH

Active, not recruiting

CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies

B-cell Chronic Lymphocytic Leukemia | B-cell Non Hodgkin Lymphoma

United States
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukaemia (CLL) | Multiple Myeloma (MM) | B-Cell Non-Hodgkin Lymphoma (NHL)

France, Australia, Germany, Korea, Republic of, United Kingdom, Hungary, Poland, Singapore
Ronald Levy
Pfizer

Completed

A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas

Lymphoma | Lymphoma, Non-Hodgkin | Lymphomas: Non-Hodgkin | Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell

United States
Adam Kittai

Recruiting

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Transformed B-Cell Non-Hodgkin Lymphoma | Refractory Transformed Non-Hodgkin Lymphoma | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma | Recurrent Transformed... and other conditions

United States
Hoffmann-La Roche

Completed

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

B-cell Non-Hodgkin Lymphoma

United States, Spain, Korea, Republic of, France, Austria, Poland
Dana-Farber Cancer Institute
Sanofi; Genzyme, a Sanofi Company

Terminated

Cyclophosphamide and Alemtuzumab In Lymphoma

Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma

United States
Acrotech Biopharma Inc.

Completed

Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large B-cell Lymphoma

United Kingdom, United States
AstraZeneca
Parexel

Active, not recruiting

Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL)

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

United States, Korea, Republic of, Canada, United Kingdom, Spain, France, Denmark
Amgen

Completed

Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL

B-Cell Non Hodgkin Lymphoma

United States, Spain, United Kingdom, Belgium, Italy, Australia, Canada, Puerto Rico
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Aggressive Non-Hodgkin... and other conditions

United States
Sanofi

Completed

Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's Lymphoma

Lymphoma | Non-Hodgkin

United States
Robert Lowsky
National Cancer Institute (NCI)

Completed

CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma

Acute Myeloid Leukemia | Hodgkin Lymphoma | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome | B-Cell Non-Hodgkin Lymphoma | Myeloproliferative Neoplasm | T-Cell Non-Hodgkin Lymphoma

United States
Sana Biotechnology

Recruiting

Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID) (VIVID)

Non Hodgkin's Lymphoma | Large B-cell Lymphoma

United States
Yogen Saunthararajah

Completed

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies

T-cell Lymphoma | Indolent B-cell Lymphoma | Aggressive B-cell Lymphoma | Non-Hodgkin's Lymphomas

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma

Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent Aggressive Non-Hodgkin Lymphoma | Recurrent Burkitt Lymphoma | Recurrent Transformed B-Cell Non-Hodgkin Lymphoma

United States
University Hospital Southampton NHS Foundation...

Completed

A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL) (ACCEPT)

Non Hodgkin Lymphoma

United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma

United States
Fox Chase Cancer Center
National Cancer Institute (NCI)

Completed

Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Lymphoma | Leukemia

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Amgen

Active, not recruiting

A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance

Acute Lymphoblastic Leukemia | B-cell Non Hodgkin Lymphoma | Pre B-Cell Acute Lymphoblastic Leukaemia

United States
Masonic Cancer Center, University of Minnesota

Active, not recruiting

FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL

Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | NHL | High-grade B-cell Lymphoma

United States
Bristol-Myers Squibb

Completed

Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma

United States, France, Spain, Germany
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

B-cell Non-Hodgkin Lymphoma

United States, Canada, Belgium, Spain, United Kingdom
AbbVie

Recruiting

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

Diffuse Large B-Cell Lymphoma | Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia | B Cell Malignancies

United States, Israel, Australia, France, United Kingdom, Belgium, Spain
Molecular Templates, Inc.

Terminated

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)

Non-hodgkin Lymphoma

United States
University of Washington
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases

Follicular Lymphoma | Marginal Zone Lymphoma | Indolent B-Cell Non-Hodgkin Lymphoma

United States
Altor BioScience

Terminated

QUILT-3.002: ALT-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma

United States
Seagen Inc.

Terminated

A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma | Diffuse Large B-cell Lymphoma | DLBCL | Grade 3 Follicular Lymphoma

United States
Alexion Pharmaceuticals
Portola Pharmaceuticals

Completed

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

Follicular Lymphoma (FL/Indolent NHL) | Aggressive NHL (a NHL) | Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) | T-cell Lymphoma (PTCL and CTCL) | B-cell Non Hodgkin Lymphoma (NHL)

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent... and other conditions

United States
TCR2 Therapeutics

Completed

TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Follicular Lymphoma | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma

United States
CRISPR Therapeutics AG

Recruiting

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Follicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | B-cell Malignancy | Large B-cell Lymphoma | Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

United States
Mayo Clinic

Recruiting

Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

Indolent B-Cell Non-Hodgkin Lymphoma | Recurrent Indolent Non-Hodgkin Lymphoma | Refractory Indolent Non-Hodgkin Lymphoma | Recurrent Indolent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent B-Cell Non-Hodgkin Lymphoma

United States
Molecular Templates, Inc.

Terminated

PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma

Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma | Non-hodgkin Lymphoma,B Cell

United States
Gilead Sciences

Terminated

Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

Non-Hodgkin Lymphoma

United States, France
Debiopharm International SA

Completed

Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL

Diffuse Large B-Cell Lymphoma | B-cell Non-Hodgkin's Lymphoma

United States, Czechia, Bulgaria, Belgium, Hungary, Ukraine, Italy, Poland, Switzerland
TG Therapeutics, Inc.

Completed

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

B-cell Lymphoma | Marginal Zone Lymphoma | Primary Central Nervous System Lymphoma | Waldenstrom's Macroglobulinemia | Non-Hodgkins Lymphoma | Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
University of Washington
AstraZeneca

Recruiting

Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma

B-Cell Non-Hodgkin Lymphoma | Primary Mediastinal (Thymic) Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Transformed Follicular Lymphoma to Diffuse...

United States
Antengene Biologics Limited

Recruiting

A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas (PROBE)

Advanced Solid Tumor | Metastatic Solid Tumor | Mature B-cell Non-Hodgkin Lymphoma

United States, Australia
Thomas Jefferson University
National Cancer Institute (NCI)

Recruiting

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent Adult Non-Hodgkin Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Indolent Adult Non-Hodgkin...

United States

Clinical Trials on B-Cell Non-Hodgkin Lymphoma in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations